NEW DELHI, Apr 10: Shasun Pharmaceuticals today said it has entered into a licensing agreement with Switzerland- based Debiopharm for the manufacturing and commercialisation of Huperzine-A, a drug used in the treatment of Alzheimer’s disease.
As per the agreement, Shasun Pharmaceuticals would be able to use the Debiopharm technology for manufacturing synthetic Huperzine-A and commercialise it, Shasun Pharmaceuticals said in a filing to the BSE.
“It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network,” Shasun Pharmaceuticals President Michel Spagnol said.
Huperzine-A is a potent and reversible acetylcholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer’s disease.
Commenting on the development Debiopharm Group President Mauvernay said: “We are excited to have the opportunity to add value to this technology while contributing to improve people’s quality of life.”
(PTI)
Trending Now
E-Paper
Follow our WhatsApp channel